Paxlovid more effective in older, vaccinated COVID-19 patients, research shows Researchers looked at data for more than 180,000 patients in Israel who had tested positive for COVID-19.
Copy link to page Download PDF
Paxlovid, a combination of nirmatrelvir and ritonavir, works by inhibiting a protease required for viral replication Shutterstock.com
The COVID-19 antiviral Paxlovid (nirmatrelvir + ritonavir; Pfizer) is associated with a 46% reduced risk of progression to severe COVID-19 or mortality, regardless of vaccination status, study results published in Clinical Infectious Diseases have suggested.
Get unlimited access to all content You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Get unlimited access to all content You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
Already an RPS member or registered? Log in
Become a member of the RPS or subscribe to continue reading and access the full range of information and news on pharmacy.
Become a member or subscribe
Register for free to keep on reading Access two premium articles as a registered user.
Register
Already an RPS member or registered? Log in
Last updated 8 June 2022 16:12